Novadip Biosciences Raises Additional $39.1 Million

Novadip Biosciences, a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has raised an additional EUR 40 million ($39.1 million) in a Series B...

Biofuture

Innovators & Investors Come Together to Shape the Future of Therapeutics 550+ ATTENDEES INCLUDING BIOPHARMA, LIFE SCIENCE, DIGITAL MEDICINE, INVESTORS